PSNL - Personalis stock soars afterhours after providing upbeat Q4 and FY revenue outlook

January, 04 2023 05:12 PM Personalis Inc.

Shares of Personalis ( NASDAQ: PSNL ) rose 10% after the bell on Wednesday after it forecasted fourth quarter revenue of about $16.7 million, and said it expects full-year revenue of $65 million, above its previously provided range of $63 million to $64 million.
The Seeking Alpha consensus for Q4 revenue is $15.34 million and $63.64 million for full-year.
The cancer genomics company expects preliminary revenue from biopharma and other customers to be $15.8 million in Q4 vs. $15.4 million last year. Q4 Preliminary revenue from biopharma and other customers includes estimated revenue from Natera of $8.2 million.
Q4 preliminary revenue from the U.S. Department of Veterans Affairs Million Veterans Program (VA MVP) is expected to be $0.9 million, compared with $5.3 million last year.
Preliminary cash, cash equivalents, and short-term investments is estimated to be $167.0 million as of December 31, 2022, the company said.
The company said it expects 2022 preliminary revenue from biopharma and other customers to be $56.6 million, with an estimated revenue contribution of $26.5 million from Natera.
Preliminary revenue from the VA MVP is $8.4 million for 2022 vs $45.7 million in 2021.

For further details see: